BioCentury | Nov 4, 2013

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
BioCentury | Dec 3, 2012

A tale of two adjuvants

The different results from FDA's panel reviews of Q-Pan H5N1 influenza vaccine from GlaxoSmithKline plc and Heplisav HBV vaccine from Dynavax Technologies Corp. provide three clear messages to companies developing adjuvanted vaccines: the larger the...
BC Week In Review | May 9, 2011
Clinical News

Etubics preclinical data

In mice, vaccination with Etubics' breast cancer adenovirus serotype 5 (Ad5) vector vaccine containing the gene for epidermal growth factor receptor 2 ( EGFR2 ; HER2; ErbB2 ; neu) induced both a traditional antibody response and...
BC Innovations | Jun 17, 2010
Cover Story

Breast cancer prophylaxis

Although the recent FDA approval of Dendreon Corp. 's Provenge therapeutic vaccine for prostate cancer finally has cemented immunotherapy's place in the cancer armamentarium, the development of prophylactic cancer vaccines has lagged far behind. One...
BC Week In Review | Jun 7, 2010
Company News

TapImmune, Mayo Clinic deal

The clinic granted TapImmune an exclusive option to license its breast cancer vaccine technology after Phase I testing. The clinic plans to file an IND in the next 6-8 months for a Phase I trial...
BC Week In Review | Jul 6, 2009
Clinical News

Breast cancer vaccine: Phase I data

Data from an Austrian Phase I trial showed that Pevion's breast cancer vaccine was well tolerated and elicited an immune response against peptide antigens and HER2 in 8 of 10 patients with advanced breast cancer...
BioCentury | Apr 7, 2008

Takeda fills a gap

Takeda Pharmaceutical Co. Ltd. 's decision last week to in-license Cell Genesys Inc. 's GVAX vaccine for prostate cancer is the first significant deal by a pharma company in the cancer immunotherapy space in about...
BC Week In Review | Apr 23, 2007
Clinical News

Ii-Key/HER2/neu cancer vaccine cancer data

GNBT's AE37 breast cancer vaccine significantly reduced regulatory T cells after 6 months in all 6 vaccinated patients (p=0.002). Researchers said that fewer regulatory T cells, which inhibit immune responses, could result in more robust...
BioCentury | Nov 13, 2006

Biomira chronicles

Biomira chronicles Weekly stock price for Biomira (TSX:BRA; BIOM) on the Toronto exchange tracked against selected events since 2000. A. 6/29/00 - BRA reacquires rights to Theratope breast cancer vaccine from Chiron, which obtained co-development and...
BioCentury | Nov 13, 2006

Smaller shots on goal

Biomira Inc. has languished since its Theratope breast cancer vaccine failed a Phase III trial in September 2002. The company's initial response was to switch focus to a follow-on vaccine program, Stimuvax , which produced promising...
Items per page:
1 - 10 of 25